<DOC>
	<DOCNO>NCT00004227</DOCNO>
	<brief_summary>RATIONALE : Radiation therapy use high-energy x-rays damage tumor cell . Monoclonal antibody cetuximab locate tumor cell either kill deliver tumor-killing substance without harm normal cell . It yet know radiation therapy effective without cetuximab cancer oropharynx , hypopharynx , larynx . PURPOSE : Randomized phase III trial compare effectiveness radiation therapy without cetuximab treat patient stage III stage IV cancer oropharynx , hypopharynx , larynx .</brief_summary>
	<brief_title>Radiation Therapy With Without Cetuximab Treating Patients With Stage III Stage IV Cancer Oropharynx , Hypopharynx , Larynx</brief_title>
	<detailed_description>OBJECTIVES : - Compare rate locoregional disease control maintain 1 year patient advance squamous cell carcinoma oropharynx , hypopharynx , larynx treat radiotherapy without concurrent cetuximab . - Compare response rate , progression-free survival overall survival rate , quality life patient treat regimen . - Compare acute late toxicity regimens patient . - Determine tumor epidermal growth factor receptor level patient treat regimen . OUTLINE : This randomize , multicenter study . Patients stratify Karnofsky performance status ( 60-80 % vs 90-100 % ) , nodal stage ( N0 v N+ ) , tumor stage ( T1-3 v T4 ) , radiotherapy schedule ( concurrent boost vs daily v twice daily ) . Patients randomize 1 2 treatment arm : - Arm I : Patients undergo radiotherapy begin day 1 . Patients assign 1 3 radiotherapy group : - Group 1 : Patients undergo concurrent boost radiotherapy comprise radiotherapy daily 5 day week 3.5 week follow radiotherapy twice daily 5 day week 2.5 week . - Group 2 : Patients undergo radiotherapy daily 5 day week 7 week . - Group 3 : Patients undergo radiotherapy twice daily 5 day week 6-6.5 week . - Arm II : Patients receive test dose cetuximab IV 10 minute day 1 . Patients experience grade 4 anaphylactic reaction receive load dose cetuximab IV 2 hour begin 30 minute completion test dose . Patients receive maintenance cetuximab IV 1 hour day 8 . Maintenance cetuximab repeat every week 7 course . Beginning day 8 , patient undergo radiotherapy arm I concurrently maintenance cetuximab . There must hour interval completion cetuximab infusion start radiotherapy . Patients N1 neck disease initial presentation undergo neck dissection 4-8 week completion radiotherapy . Quality life assess initiation study therapy , 8 week , every 4 month 1 year . Patients follow 8 week , every 4 month 2 year , every 6 month 3 year . PROJECTED ACCRUAL : Approximately 416 patient ( 208 per arm ) accrue study within approximately 5 year .</detailed_description>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven advanced squamous cell carcinoma oropharynx , hypopharynx , larynx Stage III OR Stage IV without distant metastasis Measurable disease Tumor tissue available immunohistochemical assay epidermal growth factor receptor expression PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 1 year Hematopoietic : Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Hepatic : Bilirubin great 1.5 mg/dL SGOT SGPT great 2 time upper limit normal Renal : Creatinine great 1.5 mg/dL OR Creatinine clearance least 50 mL/min Calcium normal Other : Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Medically able withstand course definitive radiotherapy No medical psychologic condition would preclude informed consent compliance No malignancy within past 3 year except basal cell skin cancer preinvasive carcinoma cervix PRIOR CONCURRENT THERAPY : Biologic therapy : No prior cetuximab murine monoclonal antibody Chemotherapy : At least 3 year since prior systemic chemotherapy No concurrent chemotherapy Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy head neck No concurrent radiotherapy Surgery : No prior surgery indicator lesion except biopsy Study radiotherapy must part postoperative regimen primary surgical resection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>stage III squamous cell carcinoma oropharynx</keyword>
	<keyword>stage IV squamous cell carcinoma oropharynx</keyword>
	<keyword>recurrent squamous cell carcinoma oropharynx</keyword>
	<keyword>stage III squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage IV squamous cell carcinoma hypopharynx</keyword>
	<keyword>recurrent squamous cell carcinoma hypopharynx</keyword>
	<keyword>stage III squamous cell carcinoma larynx</keyword>
	<keyword>stage IV squamous cell carcinoma larynx</keyword>
	<keyword>recurrent squamous cell carcinoma larynx</keyword>
</DOC>